METASTATIC FALLOPIAN TUBE CARCINOMA
Clinical trials for METASTATIC FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: METASTATIC FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: METASTATIC FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:25 UTC
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) is safe and effective for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 participan…
Matched conditions: METASTATIC FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC